Fig. 2.
Cumulative incidence of HCC (before PMS) (Kaplan-Meier analysis).
(A) All patients taking ETV, TDF, or TAF. (B) Patients with liver cirrhosis. (C) Patients without liver cirrhosis. ETV, entecavir; HCC, hepatocellular carcinoma; PMS, propensity score matching; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.
